Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAA2 | P54646 | 5/20 | 0.46 |
| ▸ | ACKR3 | P25106 | 10/20 | 0.44 |
| ▸ | FAAH | O00519 | 4/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.42 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.42 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.42 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.42 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.42 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12955050 | 0.96 | PRKAA2 (0.47) | PRKAA2ACKR3FAAHMGLLPRKAB2 | |
| Trifluoroacetic Acid SCHEMBL1020788 | 0.90 | PRKAA2 (0.51) | PRKAA2ACKR3FAAHMGLLPRKAB2 | |
| SCHEMBL1019799 | 0.87 | PRKAA2 (0.47) | PRKAA2ACKR3PRKAB2PRKAG1PRKAA1 | |
| SCHEMBL12954997 | 0.86 | PRKAA2 (0.52) | PRKAA2ACKR3FAAHMGLLPRKAB2 | |
| SCHEMBL1020431 | 0.83 | ACKR3 (0.42) | PRKAA2ACKR3PRKAB2PRKAG1PRKAA1 | |
| SCHEMBL13663440 | 0.82 | PRKAA2 (0.46) | PRKAA2FAAHMGLLPRKAB2PRKAG1 | |
| SCHEMBL1019959 | 0.82 | FAAH (0.43) | PRKAA2FAAHPRKAB2PRKAG1PRKAA1 | |
| SCHEMBL1019018 | 0.80 | ACKR3 (0.47) | PRKAA2ACKR3PRKAB2PRKAG1PRKAA1 | |
| Trifluoroacetic Acid SCHEMBL1018638 | 0.79 | PRKAB2 (0.48) | PRKAA2ACKR3FAAHPRKAB2PRKAG1 | |
| Trifluoroacetic Acid SCHEMBL1016969 | 0.77 | PRKAB2 (0.46) | PRKAA2ACKR3PRKAB2PRKAG1PRKAA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314091-B2 | N-benzyl,N'-arylcarbonylpiperazine derivatives | MSD OSS B.V. (NL) | 2012-11-20 | — | — | US | disclosed |
| EP-2190827-B1 | N-BENZYL-N'-ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | ORGANON NV (NL) | 2011-01-12 | — | — | EP | disclosed |
| EP-2190827-A1 | N-BENZYL, N' -ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | N.V. Organon (NL) | 2010-06-02 | — | — | EP | disclosed |
| US-20090264416-A1 | N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES | N.V. ORGANON AND PHARMACOPEIA, INC. | 2009-10-22 | — | — | US | disclosed |
| WO-2009024550-A1 | N-BENZYL, N' -ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | N.V. ORGANON (NL) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264416-A1 | N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES | NPC1L1, NPC1, ABCB11 | PRKAA2 3532/4885ACKR3 1939/4885FAAH 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.